PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

被引：0

作者：

Marzia Del Re

Riccardo Marconcini

Giulia Pasquini

Eleonora Rofi

Caterina Vivaldi

Francesco Bloise

Giuliana Restante

Elena Arrigoni

Chiara Caparello

Maria Grazia Bianco

Stefania Crucitta

Iacopo Petrini

Enrico Vasile

Alfredo Falcone

Romano Danesi

机构：

[1] Clinical Pharmacology and Pharmacogenetics Unit,Department of Clinical and Experimental Medicine

[2] University of Pisa,Department of Translational Research and New Technologies in Medicine and Surgery

[3] Medical Oncology Unit,Department of Translational Research and New Technologies in Surgery and Medicine

[4] University of Pisa,undefined

[5] General pathology,undefined

[6] University of Pisa,undefined

来源：

British Journal of Cancer | 2018年 / 118卷

关键词：

PD-L1; exosomes; circulating nucleic acids; immunotherapy; predictive biomarker; pharmacogenetics; nivolumab; pembrolizumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：820 / 824

页数：4

共 50 条

[1] PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
Del Re, Marzia
Marconcini, Riccardo
Pasquini, Giulia
Rofi, Eleonora
Vivaldi, Caterina
Bloise, Francesco
Restante, Giuliana
Arrigoni, Elena
Caparello, Chiara
Bianco, Maria Grazia
Crucitta, Stefania
Petrini, Iacopo
Vasile, Enrico
Falcone, Alfredo
Danesi, Romano
BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 820 - 824
[2] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
Masuda, Ken
Horinouchi, Hidehito
Tanaka, Midori
Higashiyama, Ryoko
Shinno, Yuki
Sato, Jun
Matsumoto, Yuji
Okuma, Yusuke
Yoshida, Tatsuya
Goto, Yasushi
Yamamoto, Noboru
Ohe, Yuichiro
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
[3] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
Sui, Xinbing
Ma, Junhong
Han, Weidong
Wang, Xian
Fang, Yong
Li, Da
Pan, Hongming
Zhang, Li
ONCOTARGET, 2015, 6 (23) : 19393 - 19404
[4] Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors
Salvia, Roser
Rico, Laura G.
Moran, Teresa
Bradford, Jolene A.
Ward, Michael D.
Drozdowskyj, Ana
Climent-Marti, Joan
Martinez-Caceres, Eva M.
Rosell, Rafael
Petriz, Jordi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
[5] PD-1 and PD-L1 antibodies for melanoma
Tsai, Katy K.
Zarzoso, Ines
Daud, Adil I.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
[6] Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
Sun, J.
Yang, Q.
Chen, M.
Gu, J.
Zheng, L.
Yu, Y.
Li, F.
Zhang, L.
Niu, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S451 - S451
[7] PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas
Perottet, Jeremy
Le Goff, Emeline
Legoupil, Delphine
Quere, Gilles
Schick, Ulrike
Marcorelles, Pascale
Uguen, Arnaud
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (02) : 161 - 165
[8] PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
Abdel-Rahman, Omar
IMMUNOTHERAPY, 2016, 8 (09) : 1081 - 1090
[9] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, Mengke
Yi, Ming
Li, Ning
Luo, Suxia
Wu, Kongming
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
[10] Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
Musaelyan, Aram A. A.
Lapin, Sergey L. V.
Urtenova, Margarita A. A.
Odintsova, Svetlana V. V.
Chistyakov, Ivan V. V.
Ulitin, Andrey M. M.
Akopov, Andrey L. L.
Orlov, Sergey V. V.
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (03)

← 1 2 3 4 5 →